{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Product&page=14",
    "query": {
      "intervention": "Study Product",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 15824,
    "total_pages": 1583,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Product&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Product&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T16:06:55.322Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01517373",
      "title": "Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 10 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 50 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 304,
      "start_date": "2012-02",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 23,
      "location_summary": "Roseville, California • San Diego, California • Walnut Creek, California + 17 more",
      "locations": [
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01517373"
    },
    {
      "nct_id": "NCT01016054",
      "title": "A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma",
        "Ovarian Cancer",
        "Ovarian Diseases",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "AGS-8M4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2009-10",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2013-02-27",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01016054"
    },
    {
      "nct_id": "NCT06071702",
      "title": "IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Stenosis",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "IoNIR Ridaforolimus-Eluting Coronary Stent System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medinol Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-07",
      "completion_date": "2026-12-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 1,
      "location_summary": "Roslyn, New York",
      "locations": [
        {
          "city": "Roslyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06071702"
    },
    {
      "nct_id": "NCT04783545",
      "title": "Phase I Study of VLX-1005 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety and Tolerability in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "VLX-1005",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veralox Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2021-03-24",
      "completion_date": "2022-01-11",
      "has_results": false,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04783545"
    },
    {
      "nct_id": "NCT02829372",
      "title": "Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Expressing Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CD3/HER2 bispecific monoclonal antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2016-05",
      "completion_date": "2019-05",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 4,
      "location_summary": "Fairway, Kansas • Detroit, Michigan • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829372"
    },
    {
      "nct_id": "NCT06378801",
      "title": "Radicle Relaxation 24: A Study of Health and Wellness Products on Stress and Related Health Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress"
      ],
      "interventions": [
        {
          "name": "Placebo Control Form 1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Relaxation Active Study Product 1.1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 2",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Relaxation Active Study Product 2.1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 3",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Relaxation Active Study Product 3.1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Control Form 4",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Relaxation Active Study Product 4.1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Relaxation Active Study Product 4.2",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Radicle Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "105 Years",
        "sex": "ALL",
        "summary": "21 Years to 105 Years"
      },
      "enrollment_count": 1700,
      "start_date": "2024-02-29",
      "completion_date": "2024-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 1,
      "location_summary": "Del Mar, California",
      "locations": [
        {
          "city": "Del Mar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06378801"
    },
    {
      "nct_id": "NCT04477512",
      "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2021-02-19",
      "completion_date": "2025-09-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04477512"
    },
    {
      "nct_id": "NCT00072228",
      "title": "Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "soblidotin",
          "type": "DRUG"
        },
        {
          "name": "chemotherapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Daiichi Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 2,
      "location_summary": "Albuquerque, New Mexico • New York, New York",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072228"
    },
    {
      "nct_id": "NCT01266967",
      "title": "A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma and Brain Metastases"
      ],
      "interventions": [
        {
          "name": "GSK2118436",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2011-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266967"
    },
    {
      "nct_id": "NCT05516992",
      "title": "Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lumbar Degenerative Disc Disease"
      ],
      "interventions": [
        {
          "name": "SB-01 For Injection",
          "type": "DRUG"
        },
        {
          "name": "Sham Needle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spine BioPharma, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 417,
      "start_date": "2022-08-19",
      "completion_date": "2025-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-11-07T16:06:55.322Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Napa",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05516992"
    }
  ]
}